Amgen
header logo

Terms of Use

The information contained on this site is for healthcare professionals only.

I am a healthcare professional from
Choose a Country ▼

AMGEN IS A
WORLD LEADER
IN THE DEVELOPMENT
AND MANUFACTURE
OF BIOLOGIC
MEDICINES

Amgen is a pioneer in the development and manufacture of therapeutic antibodies
Therapeutic antibodies such as Repatha® are genetically engineered molecules, designed to ensure high specificity and functionality.1 They are biologic medicines, produced using biotechnology – that is, through the genetic modification of living cells or organisms.2

Antibody (immunoglobulin secreted by B cells)1

Amgen is a forerunner in PCSK9i innovation
Amgen has been at the forefront of research and development in PCSK9 inhibition for more than a decade.

*In the study, 2690 recent MI patients received Repatha®, 2254 of whom achieved LDL-C levels <55 mg/dl.
25% RRR reported as the key secondary endpoint: composite of cardiovascular death, MI or stroke. HR: 0.75; 95% CI: 0.62-0.91; p=0.003. ARR: 3.2%; 95% CI: 1.2-5.2.
ACS = Acute coronary syndrome; ARR = Absolute risk reduction; CV = Cardiovascular; CVD = Cardiovascular disease; EAS = European Atherosclerosis Society; ESC = European Society of Cardiology; EVOPACS = EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes; FOURIER = Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk; LDL-C = Low-density lipoprotein cholesterol; LDL-R = LDL receptor; MI = Myocardial infarction; PCSK9 = Protein convertase subtilisin/kexin type 9; RRR = Relative risk reduction.
  1. Brekke OH, Sandlie I. Nat Rev Drug Discov. 2003;2:52-62.
  2. Revers L, Furczon E. Can Pharmacists J (Ottawa). 2010;143(3):134-9.
  3. Sabatine MS, et al. N Engl J Med. 2017;376:1713-22.
  4. EMA Summary of opinion 22/03/2018. Available at: https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-repatha-ii-17-g_en.pdf. Accessed: December 2019.
  5. Gencer B, et al. JAMA Cardiol. 2020; Online first. doi:10.1001/jamacardio.2020.0882.

By clicking the 'DOWNLOAD' button below you will immediately begin downloading the Reporting Systems Appendix
Return to previous page DOWNLOAD